Misoone (Misoprostol)

Misoprostol activates prostaglandin E1 (EP) receptors in the stomach and uterus. In the gastric lining, this action raises mucus and bicarbonate production while lowering acid secretion. In uterine tissue, EP‑receptor stimulation causes calcium‑mediated muscle contraction, aiding cervical ripening and uterine contractility.

The appropriate dose of Misoone is determined by the prescribing clinician based on the specific indication, patient characteristics, and local treatment guidelines. No fixed dosing regimen is provided here; the prescriber will set the exact amount and schedule.

Misoone is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as misoprostol may be excreted in breast milk and affect the infant.

To order Misoone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Misoone (misoprostol) is a synthetic prostaglandin E1 analog, whereas other agents such as dinoprostone are prostaglandin E2 analogs. Misoprostol is more stable at room temperature, can be administered orally, and has a broader range of approved obstetric and gastro‑protective uses, but its side‑effect profile and dosing flexibility differ from other prostaglandins.

Misoone should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain its stability.

Misoone is supplied as an oral tablet and is taken by mouth with water. The exact timing relative to meals or other medications depends on the clinical indication and the prescriber’s instructions. For obstetric uses, the tablet may be administered in a controlled clinical setting under medical supervision.

Serious risks include uterine rupture, especially when used in high doses or in patients with a scarred uterus, severe postpartum hemorrhage, and rare but life‑threatening allergic reactions such as anaphylaxis. Immediate medical attention is required if any signs of these complications appear.

Misoone should not be used by pregnant women, individuals with known hypersensitivity to misoprostol or other prostaglandin analogs, patients with severe cardiovascular disease where uterine hyperstimulation could be hazardous, and anyone for whom a contraindicated drug interaction exists without appropriate monitoring.